دورية أكاديمية
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors.
| العنوان: | Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors. |
|---|---|
| المؤلفون: | Suzuki Y; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.; Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan., Kaneko H; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan. kanekohidehiro@gmail.com.; The Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan. kanekohidehiro@gmail.com., Okada A; Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Komuro J; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.; Department of Cardiology, Keio University School of Medicine, Tokyo, Japan., Fujiu K; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.; The Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan., Takeda N; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan., Morita H; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan., Ako J; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan., Nishiyama A; Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Yano Y; Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.; Department of Family Medicine and Community Health Duke University Durham NC, Durham, NC, USA., Ieda M; Department of Cardiology, Keio University School of Medicine, Tokyo, Japan., Node K; Department of Cardiovascular Medicine, Saga University, Saga, Japan., Yasunaga H; Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan., Komuro I; The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.; International University of Health and Welfare, Tokyo, Japan. |
| المصدر: | Hypertension research : official journal of the Japanese Society of Hypertension [Hypertens Res] 2024 Jul; Vol. 47 (7), pp. 1789-1796. Date of Electronic Publication: 2024 Apr 10. |
| نوع المنشور: | Journal Article; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9307690 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1348-4214 (Electronic) Linking ISSN: 09169636 NLM ISO Abbreviation: Hypertens Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2009- : London : Nature Publishing Group Original Publication: Toyonaka, Japan : The Society, c1992-2003 |
| مواضيع طبية MeSH: | Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors*/adverse effects , Hypertension*/drug therapy , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors*/adverse effects , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications, Humans ; Male ; Female ; Middle Aged ; Aged ; Incidence ; Blood Pressure/drug effects ; Adult |
| مستخلص: | Although several randomized clinical trials have reported the potential benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether SGLT2i can reduce incident hypertension is unknown. We analyzed individuals with diabetes who were newly prescribed SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i) in a large-scale epidemiological database. The primary outcome was the incidence of hypertension. A propensity score matching algorithm was employed to compare the subsequent development of hypertension between the SGLT2i and DPP4i groups. After propensity score matching, 5708 well-balanced pairs of SGLT2i and DPP4i users were identified. SGLT2i administration was associated with a reduced risk of hypertension (HR 0.91, 95% CI: 0.84-0.97). The advantage of SGLT2i use over DPP4i use for incident hypertension was generally consistent in several sensitivity analyses, and subgroup analyses showed that SGLT2i use was significantly associated with a lower risk of hypertension in men, patients with baseline HbA1c of <7.5%, and baseline systolic blood pressure ≥127 mmHg. Our investigation using nationwide real-world data demonstrated the potential advantage of SGLT2i over DPP4i in reducing the development of hypertension in individuals with diabetes. (© 2024. The Author(s).) |
| التعليقات: | Comment in: Hypertens Res. 2024 Jul;47(7):1892-1893. doi: 10.1038/s41440-024-01696-6. (PMID: 38658652) |
| References: | Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:556–77. (PMID: 10.1038/s41574-020-0392-232855502) Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761–72. (PMID: 10.1038/s41569-020-0406-832665641) Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–72. (PMID: 10.1161/CIRCULATIONAHA.116.02188727470878) Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34. (PMID: 10.1056/NEJMoa151592027299675) Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57. (PMID: 10.1056/NEJMoa161192528605608) Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306. (PMID: 10.1056/NEJMoa181174430990260) Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, et al. Validation of plasma biomarker candidates for the prediction of eGFR decline in patients with type 2 diabetes. Diabetes Care. 2018;41:1947–54. (PMID: 10.2337/dc18-0532299805276105325) Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. (PMID: 10.1056/NEJMoa202481632970396) Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954–60. (PMID: 10.1038/s41591-021-01536-x347119768604725) Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–8. (PMID: 10.2337/dc14-109625271206) Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42:693–700. (PMID: 10.2337/dc18-2207308943836429633) Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021;143:1735–49. (PMID: 10.1161/CIRCULATIONAHA.120.04874033554616) Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005686. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211–20. (PMID: 10.1016/S2213-8587(15)00417-926620248) Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601–10. (PMID: 10.1016/S0140-6736(12)60987-822883509) Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, et al. Association of blood pressure classification using the 2017 American College of Cardiology/American Heart Association Blood Pressure guideline with risk of heart failure and atrial fibrillation. Circulation. 2021;143:2244–53. (PMID: 10.1161/CIRCULATIONAHA.120.05262433886370) Kaneko H, Yano Y, Lee H, Lee HH, Okada A, Suzuki Y, et al. Blood pressure classification using the 2017 ACC/AHA guideline and heart failure in patients with cancer. J Clin Oncol. 2023;41:980–90. Suzuki Y, Kaneko H, Okada A, Matsuoka S, Fujiu K, Michihata N, et al. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2022;102:1147–53. (PMID: 10.1016/j.kint.2022.05.03135961884) Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–20. (PMID: 10.1093/aje/kwg23114585769) Bouchi R, Sugiyama T, Goto A, Imai K, Ihana-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13:280–91. (PMID: 10.1111/jdi.1363634309213) van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18:294–306. (PMID: 10.1038/s41581-022-00535-635145275) Consortium NDoPHRSGSiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–801. (PMID: 10.1016/S0140-6736(22)02074-8) Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovasc Diabetol. 2022;21:67. (PMID: 10.1186/s12933-022-01508-6355855909115977) Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82. (PMID: 10.1016/j.je.2016.09.009281420515602797) Fujihara K, Yamada-Harada M, Matsubayashi Y, Kitazawa M, Yamamoto M, Yaguchi Y, et al. Accuracy of Japanese claims data in identifying diabetes-related complications. Pharmacoepidemiol Drug Saf. 2021;30:594–601. (PMID: 10.1002/pds.521333629363) Hara K, Tomio J, Svensson T, Ohkuma R, Svensson AK, Yamazaki T. Association measures of claims-based algorithms for common chronic conditions were assessed using regularly collected data in Japan. J Clin Epidemiol. 2018;99:84–95. (PMID: 10.1016/j.jclinepi.2018.03.00429548842) |
| فهرسة مساهمة: | Keywords: Diabetes; Epidemiology; Hypertension; SGLT2 inhibitors |
| المشرفين على المادة: | 0 (Sodium-Glucose Transporter 2 Inhibitors) 0 (Dipeptidyl-Peptidase IV Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240410 Date Completed: 20240704 Latest Revision: 20240716 |
| رمز التحديث: | 20240717 |
| مُعرف محوري في PubMed: | PMC11224012 |
| DOI: | 10.1038/s41440-024-01649-z |
| PMID: | 38600275 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1348-4214 |
|---|---|
| DOI: | 10.1038/s41440-024-01649-z |